TMO
TMO — Healthcare
Graham: 12
Buffett: 76
Lynch: 14
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for...
Price ?
567.20
Market Cap ?
214.2B
P/E ?
32.79
P/B ?
4.20
Div Yield ?
0.30%
52W Range ?
385.46 - 610.97
200W MA ?
533.51
12
Graham-style buying rate (0-100)
Criteria breakdown
- ✓ Company size sufficient (large-cap) ? $214,181,609,472 — Uses market cap >= $2B as proxy
- ✗ Solid financial condition (CR>=2; LT debt <= NCAV) ? CR=1.50 | D/E=0.70 — Partial: checks current ratio; LT debt vs NCAV unavailable
- ✗ Uninterrupted dividends for 20 years ?
- ✗ No losses in last 10 years ? Last 5y — Met for last 5y; need 10y to evaluate
- ✓ EPS growth >= 33% over 10 years ? ~1002%
- ✗ Price-to-Book (P/B) <= 1.5 ? 4.20
- ✗ Price-to-Earnings (P/E) <= 15 ? 32.8 — Uses trailing P/E as proxy for 3y avg EPS
- ✗ Combined formula (P/E * P/B) <= 22.5 ? 137.8
- ✗ Margin of safety >= 20% ? -122% — Intrinsic via 5y avg EPS * 15
- ✗ High ROE maintained without excessive debt ? ROE=13.1% | D/E=0.70 — Approximate threshold ROE = 15%, D/E = 1.0
What is evaluated (Graham):
- Valuation discipline and buying below intrinsic value.
- Financial resilience: liquidity and prudent leverage.
- Consistent dividends and earnings over long horizons.
"The intelligent investor is a realist who sells to optimists and buys from pessimists." — Benjamin Graham
76
Buffett-style buying rate (0-100)
Criteria breakdown
- ✓ Positive and growing FCF (multi-year) ? 9,885,000,000 -> 10,067,000,000
- ✓ ROIC >= 12% sustained ? 19.5%
- ✗ High ROE (proxy for durable advantages) ? 13.1% — Consistency over years not checked
- ✓ Net profit margin >= 10% ? 15.0% — Derived from available financial filings
- ✓ Conservative leverage (D/E <= 1.0) ? 0.70
- ✓ Sustainable shareholder returns (dividend > 0%) ? 0.30% — Does not assess buybacks or payout safety
What is evaluated (Buffett):
- Durable advantages: high ROE, healthy margins.
- Balance discipline and shareholder friendly capital use.
- Positive free cash flow and efficient reinvestment.
"It is far better to buy a wonderful company at a fair price than a fair company at a wonderful price." — Warren Buffett
14
Lynch-style buying rate (0-100)
Criteria breakdown
- ✗ PEG ratio (P/E / growth) <= 1.0 ? 37.21
- ✗ Positive multi-year EPS growth (per-year >= 10%) ? ~0.9%/yr
- ✗ Conservative leverage (D/E <= 0.5) ? 0.70
- ✓ Sustainable profitability (net margin >= 5%) ? 15.0%
- ? Earnings stability (no losses in 10y) ? — No history
What is evaluated (Lynch):
- Growth at a reasonable price (PEG and EPS CAGR).
- Durable earnings with limited drawdowns.
- Conservative balance sheet and baseline profitability.
"Know what you own, and know why you own it." — Peter Lynch